Biogen Pharmachem Share Price Today | Stock Price & Biogen Pharmachem Share Screener
As of October 5, 2026, the live Biogen Pharmachem share price (BSE: BIOGEN) is ₹0.27, unchanged from the previous close, with shares trading between ₹0.26 and ₹0.27 in today's trading session, and a 52-week range of ₹0.26–₹0.84. Check BIOGEN price range for the annual price range and momentum. Use the Biogen Pharmachem stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Biogen Pharmachem opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Biogen Pharmachem Share Price Chart
Track the current stock price of Biogen Pharmachem with an interactive chart. Analyse BIOGEN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Biogen Pharmachem stock quote in one place.
The quote of ₹0.27 sits between the 52-week low of ₹0.26 and the 52-week high of ₹0.84.
Biogen Pharmachem Company Profile - Fundamental Screener
Screen Biogen Pharmachem company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BIOGEN shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Financial Services sector and the Other Financial Services industry, and it trades under ISIN INE703D01023.
Company Details
Classification
Identifiers and Leadership
Biogen Pharmachem Balance Sheet Screener
Screen BIOGEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹99, up from ₹92 in 2025.
Latest statistics put total assets at ₹99 and shareholder funds at ₹99.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 99 | 92 | 57 | 55 | 55 | 54 | 56 | 58 | 56 | 63 |
| Current Assets | 1 | 3 | 0 | 0 | 2 | 3 | 8 | 8 | 7 | 0 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 99 | 92 | 57 | 55 | 54 | 54 | 56 | 54 | 54 | 61 |
| Share Capital | 90 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 | 65 |
| Reserves & Surplus | 9 | -9 | -9 | -11 | -11 | -11 | -10 | -11 | -11 | -4 |
Biogen Pharmachem Income Statement Screener - Profit & Revenue Analysis
Screen Biogen Pharmachem income statement and profit fundamentals. Analyze BIOGEN quarterly results. Biogen Pharmachem reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹1 and net profit was ₹0.
In that period expenses were ₹2, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹3 and net profit of ₹1.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 1 | 3 | 1 | 2 | 1 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 |
| Expenses | 2 | 2 | 2 | 1 | 1 | 3 | 3 | 0 | 1 | 7 | 0 | 0 | 0 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 0 | 1 | 0 | 2 | 1 | 0 | -2 | 0 | 0 | -7 | 0 | 0 | 0 |
| Operating Profit % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.00% | -99.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 0 | 1 | 0 | 2 | 1 | 0 | -2 | 0 | 0 | -7 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 0 | 2 | 1 | 0 | -2 | 0 | 0 | -7 | 0 | 0 | 0 |
| EPS | 0.00 | 0.01 | 0.00 | 0.03 | 0.01 | 0.00 | -0.02 | 0.00 | 0.00 | -0.10 | 0.00 | 0.00 | 0.00 |
Biogen Pharmachem Cash Flow Screener - Liquidity Fundamentals
Screen BIOGEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹2, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹10 and financing activities provided ₹6.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 2 | -1 | 2 | 2 | 1 | 4 | -1 | 0 | -14 | 0 |
| Investing Activities | -10 | -33 | -2 | -2 | -1 | -4 | 2 | -1 | 14 | 4 |
Financing and Net Cash | ||||||||||
| Financing Activities | 6 | 36 | 0 | 0 | 0 | 0 | 0 | 1 | -1 | -4 |
| Net Cash Flow | -2 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Biogen Pharmachem Shareholding Pattern Screener
See Biogen Pharmachem shareholding pattern with promoter, FII, and DII holdings. Check Biogen Pharmachem promoter holding and ownership changes for BIOGEN on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 0.00%, foreign institutions 0.00%, domestic institutions 0.00% and the public 56.92%, spread across 289,155 shareholders.
The shareholder count was 289,155 in 2026-Mar, compared with 293,831 in 2026-May.
| Item | 2026-Mar | 2026-May | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 56.92% | 69.24% | 71.08% | 76.46% | 55.33% | 55.38% | 55.43% | 76.85% |
| Other Holding | 43.07% | 30.76% | 28.92% | 23.54% | 44.67% | 44.62% | 44.56% | 23.15% |
| Shareholder Count | 289,155 | 293,831 | 293,626 | 302,362 | 303,922 | 293,327 | 289,987 | 197,757 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Biogen Pharmachem. Biogen Pharmachem dividend yield can be compared with peers and other stocks in the market.
Biogen Pharmachem Stock Index Membership - Nifty & Sensex
See which indices include Biogen Pharmachem stock. Check BIOGEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Biogen Pharmachem Market Events Screener - Corporate Actions
Get Biogen Pharmachem corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Biogen Pharmachem stock events that may affect BIOGEN share price, along with derivatives, futures and options activity and sector gainers.
14 corporate actions are listed, the most recent entry being Annual General Meeting dated September 29, 2026, with a record date of September 29, 2026.
It is followed by Quarterly Result Announcement dated August 5, 2026 and Bonus dated May 15, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-29 | 2026-09-29 | Annual General Meeting | NA | 0.00% |
| 2026-08-05 | 2026-08-05 | Quarterly Result Announcement | NA | -9.38% |
| 2026-05-15 | 2026-05-15 | Bonus | 1:6 | -18.60% |
| 2026-05-14 | 2026-05-14 | Quarterly Result Announcement | NA | -7.50% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 1.75% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -2.82% |
| 2025-09-25 | 2025-09-25 | Annual General Meeting | NA | -3.85% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -1.23% |
| 2025-05-23 | 2025-05-23 | Quarterly Result Announcement | NA | 22.54% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 0.00% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -2.73% |
| 2024-09-28 | 2024-09-28 | Annual General Meeting | NA | 0.90% |
| 2024-02-01 | 2024-02-01 | Extraordinary General Meeting | NA | -10.00% |
| 2021-01-22 | 2021-01-22 | Change Of Name | NA | 0.00% |
Biogen Pharmachem Competitors Screener - Peer Stocks Comparison
Screen BIOGEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Financial Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| RRP Semiconductor | 11,070 | -1434.90 | -7 | -120.94% | -8 | 12.17 |
| OnEMI Technology Solutions | 6,722 | 20.82 | 2,209 | 63.31% | 282 | 68.63 |
| Colab Platforms | 2,597 | 535.63 | 163 | 132.81% | 5 | 6.16 |
| Algoquant Fintech | 1,918 | 41.66 | 236 | 0.34% | 33 | 51.96 |
| Spice Lounge Food Works | 1,848 | 126.82 | 162 | 52.16% | 10 | 38.50 |
| Gyftr | 1,199 | 55.25 | 380 | 2540.69% | 22 | 34.48 |
| Prime Securities | 1,015 | 216.78 | 138 | 54.36% | 14 | 57.00 |
| Wealth First Portfolio Managers | 921 | 29.29 | 71 | 18.30% | 38 | 50.94 |
| RNFI Services | 796 | 24.27 | 974 | 5.47% | 32 | 53.06 |
| Stellant Securities | 520 | 37.43 | 0 | % | 0 | 39.59 |
Biogen Pharmachem Company Announcements - News & Reports Screener
Screen BIOGEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 1, 2026.
The next most recent announcements are dated September 30, 2026 and September 17, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-17 | Closure of Trading Window | - |
| 2026-09-04 | Reg. 34 (1) Annual Report. | - |
| 2026-09-04 | Intimation Of Book Closure Pursuant To Regulation 42 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-09-04 | Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-05 | Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-05 | Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations") | - |
| 2026-08-05 | Board Meeting Outcome for Outcome Of Board Meeting Held On 5Th August 2026. | - |
| 2026-07-21 | Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations 2015 - Intimation Of Board Meeting. | - |
| 2026-07-07 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-12 | Closure of Trading Window | - |
| 2026-05-23 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-20 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-20 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-20 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-05-18 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-05-14 | Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-14 | Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations") | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹0.27, within a 52-week range of ₹0.26 to ₹0.84. The P/B ratio is 0.29. Market capitalisation stands at ₹28.40 Cr. The company operates in the Financial Services sector, in the Other Financial Services industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.